Financhill
Back

BeiGene 10K Form

Sell
25

BGNE
BeiGene

Last Price:
187.38
Seasonality Move:
11.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BGNE News And Ratings

See the #1 stock for the next 7 days that we like better than BGNE

BGNE Financial Statistics

Sales & Book Value

Annual Sales: $1.42B
Cash Flow: $-260.45M
Price / Cash Flow: 0
Annual Sales: $36.16
Price / Book: 5.21

Profitability

EPS (TTM): -9.36000
Net Income (TTM): $-959.49M
Gross Margin: $1.13B
Return on Equity: -23.11%
Return on Assets: -15.83%

BeiGene Earnings Forecast

Key BeiGene Financial Ratios

  • The Gross Profit Margin over the past 10 years for BGNE is 79.77%.
  • The Selling, General & Administrative Expenses for BGNE have been equal to 90.25% of Gross Profit Margin.
  • The Research & Development expenses have been 115.86% of Revenue.
  • The Interest Expense is -42.19% of Operating Income.
  • The Net Earning history of BGNE is -141.52% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 2 years.

BeiGene Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: BGNE
CUSIP: 07725L
Website: beigene.com

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 3.16
Quick Ratio: 2.75

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BGNE Technical Analysis vs Fundamental Analysis

Sell
25
BeiGene (BGNE) is a Sell

Is BeiGene a Buy or a Sell?

  • BeiGene stock is rated a Sell
    The current BeiGene [BGNE] share price is $187.49. The Score for BGNE is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.